Molecular and Immunologic Analysis of Tumor and/or Draining Lymph Nodes of Head and Neck Cancer Patients

Principal Investigator: Sara Pai, Massachusetts General

A Phase Th/II Rescue Study with Azacitidine, Durvalumab (MEDI4736), and Tremelimumab Combination Therapy in Recurrent or Metastatic SCCHN Subjects Who Have Progressed on Anti-PD-I, Anti-PD-PL 1, or Anti-CTLA-4 Monotherapy